The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Open accessAbstract
A tridecamer oligodeoxynucleotide, d(A-A-T-G-G-T-A-A-A-A-T-G-G), which is complementary to reiterated 3'- and 5'-terminal nucleotides of Rous sarcoma virus 35S RNA, is an efficient inhibitor of the translation of proteins specified by the viral RNA in the wheat embryo cell-free system. The inhibition specificity for oncornavirus RNA is greater than for rabbit reticulocyte mRNA or brome mosaic virus RNA. Other oligodeoxynucleotides of similar size have little or no specific effect on the RNA-directed translation. The tridecamer acts as a primer for the avian myeloblastosis virus DNA polymerase when Rous sarcoma virus heated 70S RNA is used as a template, offering evidence that it can hybridize to the RNA. The possible use of such an oligodeoxynucleotide hybridization competitor to inhibit Rous sarcoma virus replication is described in the preceding paper [Zamecnik, P. C. & Stephenson, M. L. (1978) Proc. Natl. Acad. Sci. USA. 75, 280--284].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
A Film Detection Method for Tritium‐Labelled Proteins and Nucleic Acids in Polyacrylamide Gels
BONNER, W. M., & LASKEY, R. A. (1974) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1974.tb03599.x · Cited by 8,589
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Self-citationRoberts, B. E., & Paterson, B. M. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.8.2330 · Cited by 1,208
Radioactive Labeling of Proteins in Vitro
Rice, R. H., & Means, G. E. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)62484-6 · Cited by 835
Rous sarcoma virus genome is terminally redundant: the 5' sequence.
Haseltine, W. A., Maxam, A. M., & Gilbert, W. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.3.989 · Cited by 203
RNA Dependent DNA Polymerase Activity in Mammalian Cells
Scolnick, E. M., Aaronson, S. A., Todaro, G. J., & Parks, W. P. (1971) · Nature · doi:10.1038/229318a0 · Cited by 124
Rous sarcoma virus genome is terminally redundant: the 3' sequence.
Schwartz, D. E., Zamecnik, P. C., & Weith, H. L. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.3.994 · Cited by 124
Self-citation
Cited by
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
Rosi, N. L., Giljohann, D. A., Thaxton, C. S., Lytton-Jean, A. K. R., Han, M. S., & Mirkin, C. A. (2006) · Science · doi:10.1126/science.1125559 · Cited by 1,988
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Self-citationThe current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Long Non-Coding RNAs in the Regulation of Gene Expression: Physiology and Disease
Fernandes, J. C. R., Acuña, S. M., Aoki, J. I., Floeter-Winter, L. M., & Muxel, S. M. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010017 · Cited by 644
Therapeutic Targeting of Long Non-Coding RNAs in Cancer
Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 611
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Therapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
Strategies, design, and chemistry in siRNA delivery systems
Dong, Y., Siegwart, D. J., & Anderson, D. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.004 · Cited by 572
Izant, J. G., & Weintraub, H. (1984) · Cell · doi:10.1016/0092-8674(84)90050-3 · Cited by 549
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Nucleic-acid therapeutics: basic principles and recent applications
Opalinska, J. B., & Gewirtz, A. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd837 · Cited by 537
Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J. S., & Broder, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7706 · Cited by 533
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Functional nucleic acid-based hydrogels for bioanalytical and biomedical applications
Li, J., Mo, L., Lu, C.-H., Fu, T., Yang, H.-H., & Tan, W. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00586h · Cited by 520
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Approaches for the sequence-specific knockdown of mRNA
Scherer, L. J., & Rossi, J. J. (2003) · Nature Biotechnology · doi:10.1038/nbt915 · Cited by 455
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Lennox, K. A., & Behlke, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1206 · Cited by 453
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.
Walder, R. Y., & Walder, J. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5011 · Cited by 450
Injected anti-sense RNAs specifically block messenger RNA translation in vivo.
Melton, D. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.144 · Cited by 401
Zamecnik, P. C., Goodchild, J., Taguchi, Y., & Sarin, P. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4143 · Cited by 400
Self-citationRNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Li, L., & Cohen, S. N. (1996) · Cell · doi:10.1016/s0092-8674(00)81111-3 · Cited by 331
Lemaitre, M., Bayard, B., & Lebleu, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.648 · Cited by 329
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Recent progress in non-native nucleic acid modifications
McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 300
Smith, C. C., Aurelian, L., Reddy, M. P., Miller, P. S., & Ts'o, P. O. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2787 · Cited by 297
EDER, P. S., DeVINE, R. J., DAGLE, J. M., & WALDER, J. A. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.141 · Cited by 293
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Trawick, B. N., Daniher, A. T., & Bashkin, J. K. (1998) · Chemical Reviews · doi:10.1021/cr960422k · Cited by 281
Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment
Klasa, R. J., Gillum, A. M., Klem, R. E., & Frankel, S. R. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760220798 · Cited by 280
The powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
Nucleoside Analogues as Chemotherapeutic Agents: A Review
Périgaud, C., Gosselin, G., & Imbach, J. L. (1992) · Nucleosides and Nucleotides · doi:10.1080/07328319208021748 · Cited by 277
Anfossi, G., Gewirtz, A. M., & Calabretta, B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3379 · Cited by 270
Wang, T., Upponi, J. R., & Torchilin, V. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 268
Oligonucleotide Therapies: The Past and the Present
Lundin, K. E., Gissberg, O., & Smith, C. I. E. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.070 · Cited by 267
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195
“The exciting concept was originally described in experiments blocking the replication of Rous Sarcoma Virus in infected chicken fibroblasts [60,61] but was limited by a lack of readily available reagents.”
BackgroundOligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
From “Cellular” RNA to “Smart” RNA: Multiple Roles of RNA in Genome Stability and Beyond
Michelini, F., Jalihal, A. P., Francia, S., Meers, C., Neeb, Z. T., Rossiello, F., Gioia, U., Aguado, J., Jones-Weinert, C., Luke, B., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00487 · Cited by 85
Bush, J. A., Aikawa, H., Fuerst, R., Li, Y., Ursu, A., Meyer, S. M., Benhamou, R. I., Chen, J. L., Khan, T., Wagner-Griffin, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd5991 · Cited by 77
An Antisense Oligonucleotide Primer
HOGREFE, R. I. (1999) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1999.9.351 · Cited by 48
MicroRNAs as Regulators of Phagocytosis
Gierlikowski, W., & Gierlikowska, B. (2022) · Cells · doi:10.3390/cells11091380 · Cited by 25
Metadata
- Authors
- Stephenson, M. L., & Zamecnik, P. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1978-01
- Volume
- 75
- Issue
- 1
- Pages
- 285-288
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2073115409
- Cited by
- 906
- References
- 21
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.